Cargando…

Analysis of the circulating myeloid‐derived suppressor cells during androgen deprivation therapy for prostate cancer

INTRODUCTION: The present study showed the involvement of immunosuppressive myeloid‐derived suppressor cells during the disease progression in a 69‐year‐old man with a prostate cancer. CASE PRESENTATION: The patient with metastatic PC (cT4N1M1ab) was initially treated with primary androgen deprivati...

Descripción completa

Detalles Bibliográficos
Autores principales: Kohada, Yuki, Kaiho, Yasuhiro, Takeda, Kazuya, Kuromoto, Akito, Ito, Jun, Teishima, Jun, Nakamura, Yasuhiro, Kaifu, Tomonori, Nakamura, Akira, Sato, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560438/
https://www.ncbi.nlm.nih.gov/pubmed/34755058
http://dx.doi.org/10.1002/iju5.12351
_version_ 1784592933012373504
author Kohada, Yuki
Kaiho, Yasuhiro
Takeda, Kazuya
Kuromoto, Akito
Ito, Jun
Teishima, Jun
Nakamura, Yasuhiro
Kaifu, Tomonori
Nakamura, Akira
Sato, Makoto
author_facet Kohada, Yuki
Kaiho, Yasuhiro
Takeda, Kazuya
Kuromoto, Akito
Ito, Jun
Teishima, Jun
Nakamura, Yasuhiro
Kaifu, Tomonori
Nakamura, Akira
Sato, Makoto
author_sort Kohada, Yuki
collection PubMed
description INTRODUCTION: The present study showed the involvement of immunosuppressive myeloid‐derived suppressor cells during the disease progression in a 69‐year‐old man with a prostate cancer. CASE PRESENTATION: The patient with metastatic PC (cT4N1M1ab) was initially treated with primary androgen deprivation therapy for 5 months and then chemotherapy with docetaxel, but he expired at the 8th month. In order to investigate whether myeloid‐derived suppressor cells are implicated in the cancer exacerbation during androgen deprivation therapy, we assessed the long‐term changes in peripheral blood myeloid‐derived suppressor cell fractions by using flow cytometry. While prostate‐specific antigen levels decreased after androgen deprivation therapy, the population of each myeloid‐derived suppressor cell subsets increased during disease deterioration. CONCLUSION: Increase in myeloid‐derived suppressor cells populations was correlated with prostate cancer progression.
format Online
Article
Text
id pubmed-8560438
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-85604382021-11-08 Analysis of the circulating myeloid‐derived suppressor cells during androgen deprivation therapy for prostate cancer Kohada, Yuki Kaiho, Yasuhiro Takeda, Kazuya Kuromoto, Akito Ito, Jun Teishima, Jun Nakamura, Yasuhiro Kaifu, Tomonori Nakamura, Akira Sato, Makoto IJU Case Rep Case Reports INTRODUCTION: The present study showed the involvement of immunosuppressive myeloid‐derived suppressor cells during the disease progression in a 69‐year‐old man with a prostate cancer. CASE PRESENTATION: The patient with metastatic PC (cT4N1M1ab) was initially treated with primary androgen deprivation therapy for 5 months and then chemotherapy with docetaxel, but he expired at the 8th month. In order to investigate whether myeloid‐derived suppressor cells are implicated in the cancer exacerbation during androgen deprivation therapy, we assessed the long‐term changes in peripheral blood myeloid‐derived suppressor cell fractions by using flow cytometry. While prostate‐specific antigen levels decreased after androgen deprivation therapy, the population of each myeloid‐derived suppressor cell subsets increased during disease deterioration. CONCLUSION: Increase in myeloid‐derived suppressor cells populations was correlated with prostate cancer progression. John Wiley and Sons Inc. 2021-08-01 /pmc/articles/PMC8560438/ /pubmed/34755058 http://dx.doi.org/10.1002/iju5.12351 Text en © 2021 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Kohada, Yuki
Kaiho, Yasuhiro
Takeda, Kazuya
Kuromoto, Akito
Ito, Jun
Teishima, Jun
Nakamura, Yasuhiro
Kaifu, Tomonori
Nakamura, Akira
Sato, Makoto
Analysis of the circulating myeloid‐derived suppressor cells during androgen deprivation therapy for prostate cancer
title Analysis of the circulating myeloid‐derived suppressor cells during androgen deprivation therapy for prostate cancer
title_full Analysis of the circulating myeloid‐derived suppressor cells during androgen deprivation therapy for prostate cancer
title_fullStr Analysis of the circulating myeloid‐derived suppressor cells during androgen deprivation therapy for prostate cancer
title_full_unstemmed Analysis of the circulating myeloid‐derived suppressor cells during androgen deprivation therapy for prostate cancer
title_short Analysis of the circulating myeloid‐derived suppressor cells during androgen deprivation therapy for prostate cancer
title_sort analysis of the circulating myeloid‐derived suppressor cells during androgen deprivation therapy for prostate cancer
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560438/
https://www.ncbi.nlm.nih.gov/pubmed/34755058
http://dx.doi.org/10.1002/iju5.12351
work_keys_str_mv AT kohadayuki analysisofthecirculatingmyeloidderivedsuppressorcellsduringandrogendeprivationtherapyforprostatecancer
AT kaihoyasuhiro analysisofthecirculatingmyeloidderivedsuppressorcellsduringandrogendeprivationtherapyforprostatecancer
AT takedakazuya analysisofthecirculatingmyeloidderivedsuppressorcellsduringandrogendeprivationtherapyforprostatecancer
AT kuromotoakito analysisofthecirculatingmyeloidderivedsuppressorcellsduringandrogendeprivationtherapyforprostatecancer
AT itojun analysisofthecirculatingmyeloidderivedsuppressorcellsduringandrogendeprivationtherapyforprostatecancer
AT teishimajun analysisofthecirculatingmyeloidderivedsuppressorcellsduringandrogendeprivationtherapyforprostatecancer
AT nakamurayasuhiro analysisofthecirculatingmyeloidderivedsuppressorcellsduringandrogendeprivationtherapyforprostatecancer
AT kaifutomonori analysisofthecirculatingmyeloidderivedsuppressorcellsduringandrogendeprivationtherapyforprostatecancer
AT nakamuraakira analysisofthecirculatingmyeloidderivedsuppressorcellsduringandrogendeprivationtherapyforprostatecancer
AT satomakoto analysisofthecirculatingmyeloidderivedsuppressorcellsduringandrogendeprivationtherapyforprostatecancer